FDA Emphasizes Risk Analysis, Labeling Details In Interoperability Draft Guidance

For manufacturers designing devices intended to be interoperable with other systems, FDA spelled out its premarket expectations for proper risk analyses, verification and validation studies, and suggested labeling in a Jan. 25 draft guidance.